Glenmark gets approval to trial favipiravir for Covid-19 in India

1st May 2020 (Last Updated May 1st, 2020 09:52)

Glenmark Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) to evaluate antivirial drug favipiravir in clinical trials to treat patients with Covid-19.

Favipiravir is a generic version of Fujifilm Toyama Chemical’s influenza drug Avigan, which holds approval in Japan for treating new influenza virus infections.

Glenmark developed the drug’s API and formulations internally. Following the regulatory approval, the new trial will assess the product in Covid-19 patients with mild to moderate infection.

Read the full article here